These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22224474)

  • 1. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.
    Berger J; Stirnemann J; Bourgne C; Pereira B; Pigeon P; Heraoui D; Froissart R; Rapatel C; Rose C; Belmatoug N; Berger MG
    Br J Haematol; 2012 Apr; 157(2):274-7. PubMed ID: 22224474
    [No Abstract]   [Full Text] [Related]  

  • 2. Early access experience with VPRIV(®): recommendations for 'core data' collection.
    Hughes DA; Al-Sayed M; Belmatoug N; Bodamer O; Böttcher T; Cappellini M; Cohen IJ; Eagleton T; Elstein D; Giraldo P; Jones S; Kaplinsky C; Lund A; Machaczka M; Mengel E; Pastores GM; Rosenbaum H; Sjo M; Tiling N; Tsaftaridis P; Zimran A; Weinreb N
    Blood Cells Mol Dis; 2011 Aug; 47(2):140-2. PubMed ID: 21146428
    [No Abstract]   [Full Text] [Related]  

  • 3. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
    Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.
    Elstein D; Foldes AJ; Zahrieh D; Cohn GM; Djordjevic M; Brutaru C; Zimran A
    Blood Cells Mol Dis; 2011 Jun; 47(1):56-61. PubMed ID: 21536468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving features in type 3 Gaucher disease on long-term enzyme replacement therapy.
    Elstein D; Abrahamov A; Altarescu G; Zimran A
    Blood Cells Mol Dis; 2013 Feb; 50(2):140. PubMed ID: 23085428
    [No Abstract]   [Full Text] [Related]  

  • 7. Glucocerebroside storage in normal monocyte cultures.
    Hardy B; Teitelman-Weissman B; Chazan S; Neri A
    Biomed Pharmacother; 1987; 41(1):40-4. PubMed ID: 3607254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular basis of treatment in Gaucher's disease].
    Pocoví M
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():32-8. PubMed ID: 22230123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
    Mitrovic M; Sumarac Z; Antic D; Bogdanovic A; Elezovic I; Vukosavljevic D; Ignjatovic S; Majkic-Singh N; Suvajdzic N
    Blood Cells Mol Dis; 2012 Jun; 49(1):58-9. PubMed ID: 22459893
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzyme replacement therapy in type I Gaucher disease.
    Kay AC; Saven A; Garver P; Thurston DW; Rosenbloom BF; Beutler E
    Trans Assoc Am Physicians; 1991; 104():258-64. PubMed ID: 1845151
    [No Abstract]   [Full Text] [Related]  

  • 11. Enzyme replacement therapy in a child with Gaucher disease.
    Masood Y; Ali AS
    J Coll Physicians Surg Pak; 2006 Dec; 16(12):786-8. PubMed ID: 17125641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large soft-tissue masses in an adult patient with Gaucher disease.
    Mahajan N; Brynes R; Yano S
    J Inherit Metab Dis; 2016 Nov; 39(6):887-888. PubMed ID: 27503099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaucher disease.
    Mignot C; Gelot A; De Villemeur TB
    Handb Clin Neurol; 2013; 113():1709-15. PubMed ID: 23622393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
    Berger J; Vigan M; Pereira B; Nguyen TT; Froissart R; Belmatoug N; Dalbiès F; Masseau A; Rose C; Serratrice C; Pers YM; Bertchansky I; Camou F; Bengherbia M; Bourgne C; Caillaud C; Pettazzoni M; Berrahal A; Stirnemann J; Mentré F; Berger MG
    Clin Pharmacokinet; 2019 Apr; 58(4):469-482. PubMed ID: 30128966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing for the treasure in exceptions.
    Cox TM
    Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870
    [No Abstract]   [Full Text] [Related]  

  • 16. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
    Camou F; Viallard JF
    Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
    [No Abstract]   [Full Text] [Related]  

  • 17. Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014.
    Barranger JA; Brady RO; Grabowski GA; Mankin H; Mistry PK; Weinreb NJ
    Am J Hematol; 2014 May; 89(5):457-8. PubMed ID: 24488939
    [No Abstract]   [Full Text] [Related]  

  • 18. Hematologic response in type I Gaucher's disease after enzyme replacement therapy.
    Parco S; Bruno G; Durighello M; Giorgini R; Simeone R; Bembi B
    Haematologica; 1999 Apr; 84(4):376-7. PubMed ID: 10190956
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduction of large soft-tissue Gaucheromas with substrate reduction therapy.
    Mahajan N; Warren M; Yano S
    J Inherit Metab Dis; 2020 Mar; 43(2):375-376. PubMed ID: 31705761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gaucher disease: a century of delineation and research. Enzyme replacement therapy: model and clinical studies.
    Beutler E; Dale GL
    Prog Clin Biol Res; 1982; 95():703-16. PubMed ID: 7122644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.